Is it time to buy into these three ASX cannabis shares?

It’s been a while since there was much life in ASX cannabis shares. But as the industry matures, it’s offering new investment opportunities.
The post Is it time to buy into these three ASX cannabis shares? appeared first on Motley Fool Australia. –

medical cannabis

The marijuana business is slowly, but inexorably, moving from the world’s black markets onto global share markets.

During the initial round of exuberance, as Canada and some of the biggest states in the US legalised not just marijuana’s medicinal use but also its recreational use, most every share involved in the cannabis field saw its share price soar.

From boom to bust to renewal

Inevitably, reality came into play and when revenues didn’t match sky-high valuations the pot stock bubble burst.

In 2019 global cannabis shares – with the biggest listed on the Canadian and US exchanges – lost roughly half their value. And earlier this year, driven by the COVID-19 share market rout and a dearth of funding, cannabis shares tumbled even further.

But the past few weeks has seen numerous ASX listed pot stocks’ share prices soaring.

Three ASX cannabis shares rocketing in September

Medicinal cannabis was given the green light in Australia in 2016. Recreational use remains strictly illegal outside of the Australian Capital Territory. But there are a number of Aussie companies involved in both medical and recreational cannabis production as well as hemp, marijuana’s non-narcotic cousin.

On the hemp front, the Australian Primary Hemp Ltd (ASX: APH) share price has enjoyed a stellar few weeks, up 32% so far in September. The share price is now up 9% year-to-date and a whopping 270% since the low on 7 April. Most of the September gains came this week after the company announced it was producing hemp-based protective face masks providing 99.9% microbial reduction. This came alongside its launch of a hemp-infused hand sanitiser.

On the medicinal marijuana front, the Auscann Group Holdings Ltd (ASX: AC8) share price is up 14% so far in September. Year-to-date it’s nowhere near to recovering from the February and March selloff, with the share price still down 47% in 2020. But the recent gains are encouraging, coming after the company announced it had completed its first clinical trial of a cannabis-based capsule intended to treat nerve pain.

And on the recreational marijuana front, the Althea Group Holdings Ltd (ASX: AGH) share price is up 38% so far in September, despite falling sharply yesterday. The share price is now up 35% year-to-date and has gained an eye-popping 228% from the 23 March low.

By comparison, the All Ordinaries Index (ASX: XAO) is up 33% since 23 March.

Althea’s share price owes much of its September gains to its Canadian Standard Processing Licence announcement earlier this week. After getting the nod from Health Canada, Althea’s wholly-owned subsidiary, Peak Processing Solutions can now begin commercial cannabis operations at the company’s facility in Tecumseh, Ontario.

While the prices of these cannabis companies, and indeed throughout the industry, remain volatile, the trend for well-run ASX cannabis shares is once again upwards.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Is it time to buy into these three ASX cannabis shares? appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!